調査レポートカテゴリー： MarketsandMarkets, 世界, 医療/バイオ

Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022

コンパニオン診断（CDx）の世界市場予測（～2022年）

◆タイトル：Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022
◆商品コード：MAM-MD5463
◆調査・発行会社：MarketsandMarkets
◆発行日：2017年8月1日
◆ページ数：172
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名利用）USD5,650 ⇒換算￥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥920,950見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

 【レポートの概要】

当調査レポートでは、コンパニオン診断（CDx）の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、技術別分析、疾患別分析、需要先別分析、地域別分析、コンパニオン診断（CDx）の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The global market is projected to reach USD 6.51 Billion by 2022 from USD 2.61 Billion in 2017, at a CAGR of 20.1%. The growth of this market is majorly driven by the factors such as improvements in regulatory guidelines, growing need for targeted therapies, rising cancer incidence across the globe, and increasing collaborations and partnerships for companion diagnostics test development.
The report analyzes the companion diagnostics market by product & service, technology, indication, end user, and region. On the basis of product & service, the assay kits & reagents segment accounted for the largest share in 2016, owing to its wide range of applications in platforms such as PCR, NGS, IHC, and ISH. Based on technology, the polymerase chain reaction segment accounted for the largest share in 2016. The large share of this segment can be attributed to the advantages of PCR such as its ease of use and easy availability of kits & reagents with a quick turnaround time as compared to other technologies. Based on indication, the market is further categorized into oncology, infectious diseases, neurology, and other indications (including cardiovascular, inflammatory, and inherited diseases). In 2016, the oncology segment accounted for the largest share and is also the fastest growing segment of the market; this is primarily attributed to the growing incidence of cancer that enhanced the focus on cancer research and also broadened the role of companion diagnostics in this field. On the basis of end user, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the market in 2016. This end-user segment is also expected to register the highest CAGR during the forecast period. The largest share and growth of this market can be attributed to increasing and significant application of companion diagnostics in the drug development process.

Geographically, the global market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. In 2016, North America dominated the market, and this is primarily attributed to the presence of a structured regulatory framework in the region, large number of drug development activities, and the development and launch of several companion diagnostic products in recent years. The Asia-Pacific region is expected to witness the highest CAGR during the forecast period, owing to the growing need of tailored therapeutics for the elderly population; increasing number of hospitals and diagnostic laboratories; and growing prevalence of life-threatening diseases are driving the growth of the companion diagnostics market in this regional segment.

However, uncertain reimbursement scenarios in different countries such as the U.S., U.K., Japan, and Australia are expected to limit market growth. In 2016, F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (U.S.), and QIAGEN N.V. (Netherland) dominated the global companion diagnostics market. Some of the other players competing in this market are Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Danaher Corporation (U.S.), Almac Group (U.S.), and Sysmex Corporation (Japan).

【レポートの目次】

1 Introduction (Page No. – 16)
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered in the Report
1.3 Currency
1.4 Limitations
1.5 Stakeholders

2 Research Methodology (Page No. – 19)
2.1 Market Size Estimation
2.2 Data Triangulation
2.2.1 Key Data From Secondary Sources
2.2.2 Key Data From Primary Sources
2.2.2.1 Key Industry Insights
2.2.3 Assumptions for the Study

3 Executive Summary (Page No. – 26)

4 Premium Insights (Page No. – 30)
4.1 Global Companion Diagnostics Market Overview
4.2 Companion Diagnostics Market, By Indication
4.3 Companion Diagnostics Market, By Product & Services
4.4 Companion Diagnostics Market, By Technology

5 Market Overview (Page No. – 33)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Improvements in Regulatory Guidelines
5.2.1.2 Growing Need for Targeted Therapies
5.2.1.3 Rising Cancer Incidence Worldwide
5.2.1.4 Increasing Collaborations and Partnerships for Companion Diagnostics Test Development
5.2.2 Restraints
5.2.2.1 Uncertain Reimbursement Scenarios in Different Regions
5.2.3 Opportunities
5.2.3.1 Increasing Demand for Next-Generation Sequencing
5.2.3.2 Increasing Number of Clinical Trials to Boost the Adoption of Companion Diagnostics
5.2.3.3 Emerging Applications of Companion Diagnostics in Other Cancer Indications, Neurological Disorders, Infectious Diseases, and Cardiovascular Diseases
5.2.4 Challenge
5.2.4.1 Intellectual Property Rights Protection Issues

6 Companion Diagnostics Market, By Product & Service (Page No. – 42)
6.1 Introduction
6.2 Assay Kits and Reagents
6.3 Software & Services

7 Companion Diagnostics Market, By Technology (Page No. – 47)
7.1 Introduction
7.2 Polymerase Chain Reaction
7.3 Immunohistochemistry
7.4 In Situ Hybridization
7.5 Next-Generation Sequencing
7.6 Other Technologies

8 Companion Diagnostics Market, By Indication (Page No. – 59)
8.1 Introduction
8.2 Oncology
8.2.1 Breast Cancer
8.2.2 Lung Cancer
8.2.3 Colorectal Cancer
8.2.4 Melanoma
8.2.5 Gastric Cancer
8.2.6 Other Cancers
8.3 Neurology
8.4 Infectious Diseases
8.5 Other Indications

9 Companion Diagnostics Market, By End User (Page No. – 70)
9.1 Introduction
9.2 Pharmaceutical and Biopharmaceutical Companies
9.3 Reference Laboratories
9.4 Other End Users

10 Companion Diagnostics Market, By Region (Page No. – 77)
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 U.K.
10.3.4 Rest of Europe
10.4 Asia-Pacific
10.5 Rest of the World

11 Competitive Landscape (Page No. – 109)
11.1 Introduction
11.2 Market Ranking Analysis
11.3 Competitive Leadership Mapping
11.3.1 Visionary Leaders
11.3.2 Innovators
11.3.3 Dynamic Differentiators
11.3.4 Emerging Companies
11.4 Competitive Benchmarking
11.4.1 Strength of Product Portfolio (For 25 Players)
11.4.2 Business Strategy Excellence (For 25 Players)

*Top 25 Companies Analyzed for This Studies are – Abbott Laboratories, Inc., Agilent Technologies, Inc., Biomérieux SA, Danaher Corporation, Illumina Inc., Myriad Genetics, Inc., Qiagen N.V., Roche Diagnostics, Thermo Fisher Scientific, Inc., Arup Laboratories Inc., Sysmex Corporation, Hologic, Inc., Novartis Ag, Almac Group, Abnova Corporation Invivoscribe Technologies, Inc., Foundation Medicine, Inc., Biogenex Laboratories, Inc., Laboratory Corporation of America Holdings, Medical & Biological Laboratories Co., Ltd, Clarity Pharmaceuticals, Researchdx, Inc., Neogenomics Laboratories, Inc., Janssen Diagnostics, Siemens Healthcare Diagnostics Inc.

12 Company Profiles (Page No. – 114)
(Overview, Business Overview, Business Strategy Excellence, Recent Developments)*
12.1 F. Hoffmann-La Roche AG
12.2 Agilent Technologies, Inc.
12.3 Qiagen N.V.
12.4 Thermo Fisher Scientific Inc.
12.5 Abbott Laboratories, Inc.
12.6 Biomérieux SA
12.7 Danaher Corporation
12.8 Illumina, Inc.
12.9 Myriad Genetics, Inc.
12.10 Arup Laboratories Inc.
12.11 Sysmex Corporation
12.12 Hologic Inc.
12.13 Novartis AG
12.14 Almac Group
12.15 Abnova Corporation

*Details on Marketsandmarkets View, Overview, Overview, Business Overview, Business Strategy Excellence, and Recent Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. – 160)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Introducing RT: Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports
13.7 Author Details

List of Tables (105 Tables)

Table 1 Companion Diagnostics Reimbursement Scenario Worldwide
Table 2 Partnerships and Collaborations for Developing Ngs-Based Companion Diagnostic Tests
Table 3 List of Clinical Trials for Companion Diagnostics
Table 4 Global Companion Diagnostics Market, By Product and Service, 2015–2022 (USD Million)
Table 5 Market for Assays & Reagents, By Region, 2015–2022 (USD Million)
Table 6 North America: Market for Assays & Reagents, By Country, 2015–2022 (USD Million)
Table 7 Europe: Companion Diagnostics Market for Assays & Reagents, By Country, 2015–2022 (USD Million)
Table 8 Market for Software & Services, By Region, 2015–2022 (USD Million)
Table 9 North America: Companion Diagnostics Market for Software & Services, By Country, 2015–2022 (USD Million)
Table 10 Europe: Companion Diagnostics Market for Software & Services, By Country, 2015–2022 (USD Million)
Table 11 Global Market, By Technology, 2015–2022 (USD Million)
Table 12 Comparison of Tissue Sequencing Platforms for Detection of Ras/Braf Mutation
Table 13 Companion Diagnostics Market for PCR, By Region, 2015–2022 (USD Million)
Table 14 North America: Market for PCR, By Country, 2015–2022 (USD Million)
Table 15 Europe: Market for PCR, By Country, 2015–2022 (USD Million)
Table 16 Market for Ihc, By Region, 2015–2022 (USD Million)
Table 17 North America: Companion Diagnostics Market for Ihc, By Country, 2015–2022 (USD Million)
Table 18 Europe: Companion Diagnostics Market for Ihc, By Country, 2015–2022 (USD Million)
Table 19 Companion Diagnostics Market for Ish, By Region, 2015–2022 (USD Million)
Table 20 North America: Market for Ish, By Country, 2015–2022 (USD Million)
Table 21 Europe: Market for Ish, By Country, 2015–2022 (USD Million)
Table 22 Market for Ngs, By Region, 2015–2022 (USD Million)
Table 23 North America: Companion Diagnostics Market for Ngs, By Country, 2015–2022 (USD Million)
Table 24 Europe: Companion Diagnostics Market for Ngs, By Country, 2015–2022 (USD Million)
Table 25 Market for Other Technologies, By Region, 2015–2022 (USD Million)
Table 26 North America: Companion Diagnostics Market for Other Technologies, By Country, 2015–2022 (USD Million)
Table 27 Europe: Companion Diagnostics Market for Other Technologies, By Country, 2015–2022 (USD Million)
Table 28 Global Companion Diagnostics Market, By Indication, 2015–2022 (USD Million)
Table 29 Companion Diagnostics Market for Oncology, By Type, 2015–2022 (USD Million)
Table 30 Companion Diagnostics Market for Oncology, By Region, 2015–2022 (USD Million)
Table 31 North America: Market for Oncology, By Country, 2015–2022 (USD Million)
Table 32 Europe: Market for Oncology, By Country, 2015–2022 (USD Million)
Table 33 Market for Neurological Disorders, By Region, 2015–2022 (USD Million)
Table 34 North America: Companion Diagnostics Market for Neurological Disorders, By Country, 2015–2022 (USD Million)
Table 35 Europe: Companion Diagnostics Market for Neurological Disorders, By Country, 2015–2022 (USD Million)
Table 36 Companion Diagnostics Market for Infectious Diseases, By Region, 2015–2022 (USD Million)
Table 37 North America: Companion Diagnostics Market for Infectious Diseases, By Country, 2015–2022 (USD Million)
Table 38 Europe: Companion Diagnostics Market for Infectious Diseases, By Country, 2015–2022 (USD Million)
Table 39 Companion Diagnostics Market for Other Indications, By Region, 2015–2022 (USD Million)
Table 40 North America: Companion Diagnostics Market for Other Indications, By Country, 2015–2022 (USD Million)
Table 41 Europe: Market for Other Indications, By Country, 2015–2022 (USD Million)
Table 42 Global Market, By End User, 2015–2022 (USD Million)
Table 43 Companion Diagnostics Market for Pharmaceutical and Biopharmaceutical Companies, By Region, 2015–2022 (USD Million)
Table 44 North America: Companion Diagnostics Market for Pharmaceutical and Biopharmaceutical Companies, By Country, 2015–2022 (USD Million)
Table 45 Europe: Market for Pharmaceutical and Biopharmaceutical Companies, By Country, 2015–2022 (USD Million)
Table 46 Companion Diagnostics Market for Reference Laboratories, By Region, 2015–2022 (USD Million)
Table 47 North America: Companion Diagnostics Market for Reference Laboratories, By Country, 2015–2022 (USD Million)
Table 48 Europe: Market for Reference Laboratories, By Country, 2015–2022 (USD Million)
Table 49 Market for Other End Users, By Region, 2015–2022 (USD Million)
Table 50 North America: Market for Other End Users, By Country, 2015–2022 (USD Million)
Table 51 Europe: Market for Other End Users, By Country, 2015–2022 (USD Million)
Table 52 Companion Diagnostics Market, By Region, 2015–2022 (USD Million)
Table 53 North America: Market, By Country, 2015–2022 (USD Million)
Table 54 North America: Market, By Product & Service, 2015–2022 (USD Million)
Table 55 North America: Market, By Technology, 2015–2022 (USD Million)
Table 56 North America: Market, By Indication, 2015–2022 (USD Million)
Table 57 North America: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 58 North America: Market, By End User, 2015–2022 (USD Million)
Table 59 U.S.: Market, By Product & Service, 2015–2022 (USD Million)
Table 60 U.S.: Market, By Technology, 2015–2022 (USD Million)
Table 61 U.S.: Market, By Indication, 2015–2022 (USD Million)
Table 62 U.S.: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 63 U.S.: Market, By End User, 2015–2022 (USD Million)
Table 64 Canada: Market, By Product & Service, 2015–2022 (USD Million)
Table 65 Canada: Market, By Technology, 2015–2022 (USD Million)
Table 66 Canada: Market, By Indication, 2015–2022 (USD Million)
Table 67 Canada: Companion Diagnostics Market Size for Oncology, By Type, 2015–2022 (USD Million)
Table 68 Canada: Market, By End User, 2015–2022 (USD Million)
Table 69 Europe: Market, By Country, 2015–2022 (USD Million)
Table 70 Europe: Market, By Product & Service, 2015–2022 (USD Million)
Table 71 Europe: Market, By Technology, 2015–2022 (USD Million)
Table 72 Europe: Market, By Indication, 2015–2022 (USD Million)
Table 73 Europe: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 74 Europe: Market, By End User, 2015–2022 (USD Million)
Table 75 Germany: Market, By Product & Service, 2015–2022 (USD Million)
Table 76 Germany: Market, By Technology, 2015–2022 (USD Million)
Table 77 Germany: Market, By Indication, 2015–2022 (USD Million)
Table 78 Germany: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 79 Germany: Market, By End User, 2015–2022 (USD Million)
Table 80 France: Market, By Product & Service, 2015–2022 (USD Million)
Table 81 France: Market, By Technology, 2015–2022 (USD Million)
Table 82 France: Market, By Indication, 2015–2022 (USD Million)
Table 83 France: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 84 France: Market, By End User, 2015–2022 (USD Million)
Table 85 U.K.: Market, By Product & Service, 2015–2022 (USD Million)
Table 86 U.K.: Market, By Technology, 2015–2022 (USD Million)
Table 87 U.K.: Market, By Indication, 2015–2022 (USD Million)
Table 88 U.K.: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 89 U.K.: Market, By End User, 2015–2022 (USD Million)
Table 90 RoE: Market, By Product & Service, 2015–2022 (USD Million)
Table 91 RoE: Market, By Technology, 2015–2022 (USD Million)
Table 92 RoE: Market, By Indication, 2015–2022 (USD Million)
Table 93 RoE: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 94 RoE: Market, By End User, 2015–2022 (USD Million)
Table 95 APAC: Market, By Product & Service, 2015–2022 (USD Million)
Table 96 APAC: Market, By Technology, 2015–2022 (USD Million)
Table 97 APAC: Market, By Indication, 2015–2022 (USD Million)
Table 98 APAC: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 99 APAC: Market, By End User, 2015–2022 (USD Million)
Table 100 RoW: Market, By Product & Service, 2015–2022 (USD Million)
Table 101 RoW: Market, By Technology, 2015–2022 (USD Million)
Table 102 RoW: Market, By Indication, 2015–2022 (USD Million)
Table 103 RoW: Market for Oncology, By Type, 2015–2022 (USD Million)
Table 104 RoW: Market, By End User, 2015–2022 (USD Million)
Table 105 Rank of Companies in the Companion Diagnostics Market, 2016

List of Figures (37 Figures)

Figure 1 Research Design
Figure 2 Bottom Up Approach
Figure 3 Top Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Market Data Triangulation Methodology
Figure 6 Global Market, By Technology, 2017 vs 2022
Figure 7 Global Market, By Indication, 2017 vs 2022
Figure 8 Global Market, By Products & Services, 2017 vs 2022
Figure 9 Global Market, By End User, 2017 vs 2022
Figure 10 Geographical Snapshot of the Companion Diagnostics Market
Figure 11 Increasing Demand for Targeted Therapy is Boosting the Companion Diagnostics Market
Figure 12 Oncology Segment is Estimated to Account for the Largest Market Share in 2017
Figure 13 Assays & Reagents Segment is Estimated to Account for the Largest Market Share in 2017
Figure 14 Polymerase Chain Reaction is Estimated to Account for the Largest Market Share in 2017
Figure 15 Companion Diagnostics Market: Drivers, Restraints, Opportunities, and Challenges
Figure 16 Increasing Number of New Cancer Cases Worldwide, 2012 vs 2015 vs 2020
Figure 17 Assay Kits and Reagents Will Continue to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 18 PCR Will Continue to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 19 Oncology Segment to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 20 Pharmaceutical and Biopharmaceutical Companies Will Continue to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 21 Geographic Snapshot: Asia-Pacific Market to Register Highest Growth During the Forecast Period
Figure 22 North American Companion Diagnostics Market Snapshot
Figure 23 European Companion Diagnostics Market Snapshot
Figure 24 Asia-Pacific Companion Diagnostics Market Snapshot
Figure 25 Competitive Leadership Mapping, 2017
Figure 26 F. Hoffmann-La Roche AG: Company Snapshot (2016)
Figure 27 Agilent Technologies, Inc.: Company Snapshot (2016)
Figure 28 Qiagen N.V.: Company Snapshot (2016)
Figure 29 Thermo Fisher Scientific Inc.: Company Snapshot (2016)
Figure 30 Abbott Laboratories, Inc.: Company Snapshot (2016)
Figure 31 Biomérieux SA: Company Snapshot (2016)
Figure 32 Danaher Corporation: Company Snapshot (2016)
Figure 33 Illumina, Inc.: Company Snapshot (2016)
Figure 34 Myriad Genetics, Inc.: Company Snapshot (2016)
Figure 35 Sysmex Corporation: Company Snapshot (2016)
Figure 36 Hologic, Inc.: Company Snapshot (2016)
Figure 37 Novartis AG: Company Snapshot (2016)

【レポートのキーワード】

コンパニオン診断（CDx）、臨床検査、医薬品、治療、疾患、コンパニオン診断術

★調査レポート[コンパニオン診断（CDx）の世界市場予測（～2022年）] ( Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022 / MAM-MD5463) 販売に関する免責事項
[コンパニオン診断（CDx）の世界市場予測（～2022年）] ( Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022 / MAM-MD5463) についてEメールでお問い合わせ
◆関連調査資料◆
  • 世界のコンパニオン診断市場：ポリメラーゼ連鎖反応(PCR)、In situ ハイブリダイゼーション(ISH)、免疫組織化学(IHC)など
  • セルラー集団検診（健診）の世界市場予測（～2022年）
  • 動物診断の世界市場予測（～2022年）：診断装置、消耗品、動物検査技術
  • 世界の組織診断（Tissue Diagnostics）市場動向と予測（～2018）
  • 体外診断（IVD）の世界市場予測（～2021）：製品別、技術別（イムノアッセイ、臨床化学、分子診断、血液学）、用途別
  • デジタルPCR及びリアルタイムPCR（qPCR）の世界市場予測（～2022年）：装置、試薬
  • メタボロミクス（メタボローム解析）の世界市場予測（～2021年）：ガスクロマトグラフィー、HPLC、UPLC、NMR、マススペクトロメトリー、表面ベース質量分析、バイオインフォマティクス
  • Ｉn situハイブリダイゼーション（ISH）の世界市場予測（～2021）：技術別（FISH、CISH）、用途別、需要先別
  • 世界の分子診断市場（～2018）
  • 分子診断の世界市場予測（～2021年）

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆